In several clinical trials, anti-PD-1 antibodies, with or without CTLA-4 blockade, demonstrated dramatic and durable responses with prolonged survival in patients with metastatic MSI CRC, although approximately 50% of them had primary resistance to ICIs [12,13]. Here, PDCD1 is linked to colorectal carcinoma.